-
Mashup Score: 1Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: - 1 year(s) ago
Abstract Background N-terminal pro–B-type natriuretic peptide (NT-proBNP) is used for diagnostic and prognostic evaluation in heart failure (HF). Previous clinical trials in heart failure with mild…
Source: JACC: Heart FailureCategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 1Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial - Nature Medicine - 1 year(s) ago
A prespecified analysis of the DELIVER clinical trial shows that the sodium/glucose cotransporter 2 inhibitor dapagliflozin benefits patients categorized as having heart failure with improved ejection fraction, a class of patients at high risk of cardiac events but for which limited treatment data are available.
Source: NatureCategories: Cardiologists, Latest HeadlinesTweet-
This analysis published in @NatureMedicine suggest that patients with #HFimpEF who are symptomatic may benefit from the addition of #SGLT2i to previously instituted #GDMT to further reduce morbidity and mortality https://t.co/2DndinxTQB #HeartFailure #DELIVER @mvaduganathan https://t.co/kJ3CgPMoiJ
-
-
Mashup Score: 1Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction: - 1 year(s) ago
Abstract Background Patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) experience a high burden of symptoms, physi…
Categories: Cardiologists, Latest HeadlinesTweet-
RT @ankeetbhatt: Now out in @JACCJournals https://t.co/tfhUICS5wk; new data on health status in #DELIVER! Dapa improves #KCCQ across all cl…
-
-
Mashup Score: 5Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction: - 1 year(s) ago
Abstract Background Patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) experience a high burden of symptoms, physi…
Categories: Cardiologists, Latest HeadlinesTweet-
IMO one of the most important #DELIVER papers now out in @JACCJournals by @MkosiborodMD & @ankeetbhatt #DELIVER QoL provides data-driven implementation approach to #SGLT2i in #HFpEF: Maximize clinical benefits in those most symptomatic in your practice! https://t.co/iuOcr5HZQC https://t.co/EpRXTfKE4X https://t.co/aNPvMTrd5Q
-
-
Mashup Score: 25Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial - Nature Medicine - 1 year(s) ago
A prespecified analysis of the DELIVER clinical trial shows that the sodium/glucose cotransporter 2 inhibitor dapagliflozin benefits patients categorized as having heart failure with improved ejection fraction, a class of patients at high risk of cardiac events but for which limited treatment data are available.
Source: NatureCategories: Cardiologists, Latest HeadlinesTweet-
Evidence to suggest that Dapagliflozin in symptomatic patients with #heartfailure with improved ejection fraction reduces morbidity & mortality. @NatureMedicine https://t.co/Xhui0Zc7dQ
-
Many patients may have improvement in #LVEF w prior medical Rx. New data from #DELIVER = largest RCT data of #HFimpEF #HFimpEF face important residual risks which may be modified w new initiation of #SGLT2i. Published in @NatureMedicine by @orlyvardeny! https://t.co/kkbaMR48fM https://t.co/iWDLxWPMod
-
-
Mashup Score: 1Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study | NEJM - 1 year(s) ago
Original Article from The New England Journal of Medicine — Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study
Source: New England Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
Sadly, #MRA appears lowest in 🇺🇸 & 🇨🇦, falling below global standards. These countries ranked *last* in background #MRAs in recent RCTs like #DELIVER (actually highest in 🇷🇺 as in #STRONGHF) ? long-term legacy of Ontario post-#RALES hyperK+ safety signal https://t.co/u63l4cuxU3 https://t.co/QeM5IYMgc4
-
-
Mashup Score: 2Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: - 1 year(s) ago
Abstract Background N-terminal pro–B-type natriuretic peptide (NT-proBNP) is used for diagnostic and prognostic evaluation in heart failure (HF). Previous clinical trials in heart failure with mild…
Source: JACC: Heart FailureCategories: Cardiologists, Latest HeadlinesTweet-
RT @pmyhre: Our paper on NT-proBNP in #DELIVER published in the current @JACCJournals-HF issue. https://t.co/QeXN4aV761 Great editorial b…
-
-
Mashup Score: 1Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: - 1 year(s) ago
Abstract Background N-terminal pro–B-type natriuretic peptide (NT-proBNP) is used for diagnostic and prognostic evaluation in heart failure (HF). Previous clinical trials in heart failure with mild…
Source: JACC: Heart FailureCategories: Expert Picks, Latest HeadlinesTweet-
RT @pmyhre: Our paper on NT-proBNP in #DELIVER published in the current @JACCJournals-HF issue. https://t.co/QeXN4aV761 Great editorial b…
-
-
Mashup Score: 0
In patients with heart failure with mildly reduced or preserved ejection fraction, oral dapagliflozin improved heart failure outcomes to a similar extent in three glycaemia subgroups: normoglycaemia, prediabetes, and type 2 diabetes. Moreover, the heart failure benefits of dapagliflozin seem to be consistent across a continuous glycaemic range.
Categories: Endocrinology, Latest HeadlinesTweet-
Efficacy and safety of #dapagliflozin in patients with #heartfailure with mildly reduced or preserved ejection fraction by baseline #glycaemic status (#DELIVER): a subgroup analysis from a ... multicentre, double-blind, randomised, placebo-controlled trial https://t.co/YDLCsqRz3s
-
-
Mashup Score: 7Home | delivertrial - 1 year(s) ago
The DELIVER trial was an international randomized trial comparing dapagliflozin to placebo in patients with heart failure with mildly reduced or preserved ejection fraction.
Source: delivertrialCategories: Cardiologists, Latest HeadlinesTweet-
Inspiring #BrighamCVGrandRounds today by @scottdsolomon Describing remarkable and hopeful journey of progress in #HFpEF drug development Closing with this last chapter from #DELIVER https://t.co/A6YqOQ0bhM ICYMI Recording soon to be available: https://t.co/CtS9I3U5HZ https://t.co/2GrYYn6QWd
-
#Dapagliflozin is safe and improves outcomes irrespective of baseline NT-proBNP concentrations in #HFmrEF or #HFpEF, with the greatest absolute benefit likely seen in patients with higher NT-proBNP concentrations. https://t.co/7iYybpkvUL #JACCHF #DELIVER #SGLT2i #CardioTwitter https://t.co/MMqz5JLCNH